{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:34:23Z","timestamp":1782732863418,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00535-025-02308-x","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:47:08Z","timestamp":1761428828000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"61","author":[{"given":"Kazuki","family":"Maesaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2488-7315","authenticated-orcid":false,"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinatsu","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaharu","family":"Iio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruyasu","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hosui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2308_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2308_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"2308_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181\u2013223.","journal-title":"Liver Cancer"},{"key":"2308_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000534304","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M. Current therapeutic strategies for hepatocellular carcinoma in Japan. Liver Cancer. 2023;12:497\u2013509.","journal-title":"Liver Cancer"},{"key":"2308_CR5","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"2308_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960\u201374.","journal-title":"J Hepatol"},{"key":"2308_CR7","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.20.02672","volume":"38","author":"JD Gordan","year":"2020","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317\u201345.","journal-title":"J Clin Oncol"},{"key":"2308_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000514312","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. Liver Cancer. 2021;10:85\u201393.","journal-title":"Liver Cancer"},{"key":"2308_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"2308_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55:113\u201322.","journal-title":"J Gastroenterol"},{"key":"2308_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/hepr.13771","volume":"52","author":"K Maesaka","year":"2022","unstructured":"Maesaka K, Sakamori R, Yamada R, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res. 2022;52:630\u201340.","journal-title":"Hepatol Res"},{"key":"2308_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103048","volume":"12","author":"T Aoki","year":"2020","unstructured":"Aoki T, Kudo M, Ueshima K, et al. Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1\/PD-L1 checkpoint blockade. Cancers (Basel). 2020;12:3048.","journal-title":"Cancers (Basel)"},{"key":"2308_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3:e59125.","journal-title":"JCI Insight"},{"issue":"Suppl 2","key":"2308_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000775","volume":"4","author":"A Sasaki","year":"2020","unstructured":"Sasaki A, Kawazoe A, Eto T, et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 2020;4(Suppl 2):e000775.","journal-title":"ESMO Open"},{"key":"2308_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.021","volume":"144","author":"T Tozuka","year":"2020","unstructured":"Tozuka T, Kitazono S, Sakamoto H, et al. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment. Lung Cancer. 2020;144:71\u20135.","journal-title":"Lung Cancer"},{"issue":"2","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi Y, Kamiyama H, Ichikawa K, et al. Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 2022;82(2):292\u2013306.","journal-title":"Cancer Res"},{"key":"2308_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/hepr.13537","volume":"50","author":"K Maesaka","year":"2020","unstructured":"Maesaka K, Sakamori R, Yamada R, et al. Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. Hepatol Res. 2020;50:1091\u2013100.","journal-title":"Hepatol Res"},{"key":"2308_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"2308_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2308_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/cncr.34559","volume":"129","author":"M Nakagawa","year":"2023","unstructured":"Nakagawa M, Inoue M, Ogasawara S, et al. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer. 2023;129:590\u20139.","journal-title":"Cancer"},{"key":"2308_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298770","volume":"19","author":"S Yamaba","year":"2024","unstructured":"Yamaba S, Imai Y, Sugawara K, et al. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma. PLoS ONE. 2024;19:e0298770.","journal-title":"PLoS ONE"},{"key":"2308_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294590","volume":"19","author":"M Kai","year":"2024","unstructured":"Kai M, Hikita H, Kazuki M, et al. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter prospective observational study. PLoS ONE. 2024;19:e0294590.","journal-title":"PLoS ONE"},{"key":"2308_CR23","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"key":"2308_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","volume":"22","author":"CH Lee","year":"2021","unstructured":"Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study. Lancet Oncol. 2021;22:946\u201358.","journal-title":"Lancet Oncol"},{"key":"2308_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1399\u2013410.","journal-title":"Lancet Oncol"},{"key":"2308_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.021","volume":"189","author":"M Persano","year":"2023","unstructured":"Persano M, Rimini M, Tada T, et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023;189:112933.","journal-title":"Eur J Cancer"},{"key":"2308_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235532","volume":"15","author":"AG Singal","year":"2023","unstructured":"Singal AG, \u00d6zg\u00fcrdal K, Fan X, et al. Real-world systemic treatment patterns after atezolizumab and bevacizumab in patients with hepatocellular carcinoma in the United States. Cancers (Basel). 2023;15:5532.","journal-title":"Cancers (Basel)"},{"key":"2308_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101232","volume":"7","author":"M Wu","year":"2025","unstructured":"Wu M, Fulgenzi CAM, D\u2019Alessio A, et al. Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab. JHEP Rep. 2025;7:101232.","journal-title":"JHEP Rep"},{"key":"2308_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3350\/cmh.2023.0553","volume":"30","author":"YE Chon","year":"2024","unstructured":"Chon YE, Kim DY, Kim MN, et al. Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: a real-world study. Clin Mol Hepatol. 2024;30:345\u201359.","journal-title":"Clin Mol Hepatol"},{"key":"2308_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000512781","volume":"10","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim JH, Ryu MH, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021;10:107\u201314.","journal-title":"Liver Cancer"},{"key":"2308_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1159\/000531316","volume":"101","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka A, Kumada T, Tada T, et al. Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: clinical results show importance of hepatic reserve function. Oncology. 2023;101:624\u201333.","journal-title":"Oncology"},{"key":"2308_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194867","volume":"15","author":"ME Palmer","year":"2023","unstructured":"Palmer ME, Gile JJ, Storandt MH, et al. Outcomes of patients with advanced hepatocellular carcinoma receiving lenvatinib following immunotherapy: a real-world evidence study. Cancers (Basel). 2023;15:4867.","journal-title":"Cancers (Basel)"},{"key":"2308_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101190","volume":"6","author":"C Campani","year":"2024","unstructured":"Campani C, Pallas D, Sidali S, et al. Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies. JHEP Rep. 2024;6:101190.","journal-title":"JHEP Rep"},{"key":"2308_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3892\/ol.2024.14464","volume":"28","author":"M Kimura","year":"2024","unstructured":"Kimura M, Yamada S, Go M, et al. Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: a comparison of lenvatinib as 1st- or 2nd-line treatment. Oncol Lett. 2024;28:330.","journal-title":"Oncol Lett"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02308-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02308-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02308-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:52:27Z","timestamp":1768474347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02308-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02308-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hayato Hikita has received research grants from Chugai Pharmaceutical Co., Ltd, Eisai; MSD K. K.; and AstraZeneca, and lecture fees from Chugai Pharmaceutical Co., Ltd. Takehara has received lecture fees from Chugai Pharmaceutical Co., Ltd, Eisai; MSD K. K.; and AstraZeneca. Takahiro Kodama has received research grants from AstraZeneca, and lecture fees from Chugai Pharmaceutical Co., Ltd and AstraZeneca. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board or Ethics Committee at each participating center (UMIN 000034611). All procedures were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in the registry cohort.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}}]}}